{"id":68447,"date":"2026-06-17T22:33:23","date_gmt":"2026-06-17T14:33:23","guid":{"rendered":"https:\/\/flcube.com\/?p=68447"},"modified":"2026-06-17T22:33:24","modified_gmt":"2026-06-17T14:33:24","slug":"hengrui-pharmaceuticals-expands-dalpiciclib-label-with-nmpa-approval-for-early-breast-cancer-adjuvant-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68447","title":{"rendered":"Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced it has received <strong>additional indication approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for its <strong>CDK4\/6 inhibitor dalpiciclib<\/strong>. The expanded label now includes use in combination with <strong>endocrine therapy as adjuvant treatment<\/strong> for <strong>hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer<\/strong> in patients with <strong>high risk of recurrence<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-overview\" class=\"wp-block-heading\">Regulatory Milestone Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Dalpiciclib \u2013 CDK4\/6 inhibitor<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Adjuvant treatment of HR-positive, HER2-negative early breast cancer with high recurrence risk<\/td><\/tr><tr><td><strong>Treatment Regimen<\/strong><\/td><td>Combination with endocrine therapy<\/td><\/tr><tr><td><strong>Initial Approval<\/strong><\/td><td>2021 (China)<\/td><\/tr><tr><td><strong>Total Approved Indications<\/strong><\/td><td>3 (including new adjuvant indication)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-expanded-indication-profile-amp-clinical-significance\" class=\"wp-block-heading\">Expanded Indication Profile &amp; Clinical Significance<\/h2>\n\n\n\n<h3 id=\"h-new-adjuvant-indication\" class=\"wp-block-heading\">New Adjuvant Indication<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> HR-positive, HER2-negative early breast cancer patients with high risk of recurrence<\/li>\n\n\n\n<li><strong>Treatment Setting:<\/strong> Adjuvant therapy following primary treatment<\/li>\n\n\n\n<li><strong>Combination Partner:<\/strong> Endocrine therapy (aromatase inhibitors or other endocrine agents)<\/li>\n\n\n\n<li><strong>Clinical Rationale:<\/strong> Addresses critical unmet need in preventing disease recurrence in high-risk early-stage patients<\/li>\n\n\n\n<li><strong>Market Impact:<\/strong> Expands addressable patient population to include early-stage disease segment<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-previously-approved-metastatic-indications\" class=\"wp-block-heading\">Previously Approved Metastatic Indications<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>First-line metastatic:<\/strong> In combination with aromatase inhibitor as initial endocrine therapy for HR-positive, HER2-negative locally advanced or metastatic breast cancer<\/li>\n\n\n\n<li><strong>Second-line metastatic:<\/strong> In combination with fulvestrant for patients whose disease progressed after prior endocrine therapy<\/li>\n<\/ol>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Label Expansion Strategy:<\/strong> Successful progression from metastatic to early-stage disease demonstrates comprehensive development approach<\/li>\n\n\n\n<li><strong>Patient Population Growth:<\/strong> Early breast cancer represents significantly larger market than metastatic setting<\/li>\n\n\n\n<li><strong>Standard of Care Potential:<\/strong> Adjuvant approval positions dalpiciclib as potential new standard in high-risk early breast cancer<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Joins limited group of CDK4\/6 inhibitors with both metastatic and adjuvant approvals in China<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Reduces dependency on metastatic market while capturing earlier treatment line revenue<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-commercial-outlook\" class=\"wp-block-heading\">Competitive Landscape &amp; Commercial Outlook<\/h2>\n\n\n\n<h3 id=\"h-cdk4-6-inhibitor-market-context\" class=\"wp-block-heading\">CDK4\/6 Inhibitor Market Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Established Class:<\/strong> CDK4\/6 inhibitors represent cornerstone of HR-positive breast cancer treatment<\/li>\n\n\n\n<li><strong>Chinese Leadership:<\/strong> Dalpiciclib is among first domestically developed CDK4\/6 inhibitors with comprehensive label<\/li>\n\n\n\n<li><strong>Pricing Advantage:<\/strong> Potential cost benefits compared to imported CDK4\/6 inhibitors in Chinese market<\/li>\n\n\n\n<li><strong>Reimbursement Status:<\/strong> Likely candidate for national reimbursement given established efficacy and domestic origin<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-strategic-commercial-advantages\" class=\"wp-block-heading\">Strategic Commercial Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Full Disease Spectrum Coverage:<\/strong> Uniquely positioned across early and advanced breast cancer settings<\/li>\n\n\n\n<li><strong>Physician Familiarity:<\/strong> Established safety profile from metastatic indications supports rapid adoption in adjuvant setting<\/li>\n\n\n\n<li><strong>Healthcare System Integration:<\/strong> Comprehensive labeling facilitates inclusion in treatment guidelines and clinical pathways<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Success in China may support international regulatory filings for adjuvant indication<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-outlook\" class=\"wp-block-heading\">Strategic Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The NMPA&#8217;s approval of dalpiciclib for adjuvant treatment represents a significant milestone in Hengrui&#8217;s breast cancer franchise, transforming the drug from a metastatic-only therapy to a comprehensive solution spanning the entire disease continuum. This label expansion not only substantially increases the addressable market but also reinforces Hengrui&#8217;s position as a leader in innovative oncology therapeutics in China. The successful progression into the adjuvant setting demonstrates the company&#8217;s sophisticated clinical development capabilities and strategic vision for maximizing therapeutic impact across all stages of HR-positive breast cancer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding market adoption, revenue expectations, and competitive positioning. Actual results may differ due to market dynamics, reimbursement decisions, competitive pressures, and clinical practice patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600276_20260617_5GV5.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260617_5GV5.\"><\/object><a id=\"wp-block-file--media-82727e08-bb1f-45d6-ab14-5507d4666925\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600276_20260617_5GV5.pdf\">600276_20260617_5GV5<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600276_20260617_5GV5.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-82727e08-bb1f-45d6-ab14-5507d4666925\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received additional indication&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,2586,15,852],"class_list":["post-68447","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-hengrui-pharmaceuticals","tag-product-approvals","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received additional indication approval from China&#039;s National Medical Products Administration (NMPA) for its CDK4\/6 inhibitor dalpiciclib. The expanded label now includes use in combination with endocrine therapy as adjuvant treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer in patients with high risk of recurrence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68447\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received additional indication approval from China&#039;s National Medical Products Administration (NMPA) for its CDK4\/6 inhibitor dalpiciclib. The expanded label now includes use in combination with endocrine therapy as adjuvant treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer in patients with high risk of recurrence.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68447\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-17T14:33:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-17T14:33:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68447#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68447\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy\",\"datePublished\":\"2026-06-17T14:33:23+00:00\",\"dateModified\":\"2026-06-17T14:33:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68447\"},\"wordCount\":560,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Hengrui Pharmaceuticals\",\"Product approvals\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68447#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68447\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68447\",\"name\":\"Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-17T14:33:23+00:00\",\"dateModified\":\"2026-06-17T14:33:24+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received additional indication approval from China's National Medical Products Administration (NMPA) for its CDK4\\\/6 inhibitor dalpiciclib. The expanded label now includes use in combination with endocrine therapy as adjuvant treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer in patients with high risk of recurrence.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68447#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68447\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68447#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received additional indication approval from China's National Medical Products Administration (NMPA) for its CDK4\/6 inhibitor dalpiciclib. The expanded label now includes use in combination with endocrine therapy as adjuvant treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer in patients with high risk of recurrence.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68447","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received additional indication approval from China's National Medical Products Administration (NMPA) for its CDK4\/6 inhibitor dalpiciclib. The expanded label now includes use in combination with endocrine therapy as adjuvant treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer in patients with high risk of recurrence.","og_url":"https:\/\/flcube.com\/?p=68447","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-17T14:33:23+00:00","article_modified_time":"2026-06-17T14:33:24+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68447#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68447"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy","datePublished":"2026-06-17T14:33:23+00:00","dateModified":"2026-06-17T14:33:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68447"},"wordCount":560,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Hengrui Pharmaceuticals","Product approvals","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68447#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68447","url":"https:\/\/flcube.com\/?p=68447","name":"Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-17T14:33:23+00:00","dateModified":"2026-06-17T14:33:24+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced it has received additional indication approval from China's National Medical Products Administration (NMPA) for its CDK4\/6 inhibitor dalpiciclib. The expanded label now includes use in combination with endocrine therapy as adjuvant treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer in patients with high risk of recurrence.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68447#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68447"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68447#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68447"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68447\/revisions"}],"predecessor-version":[{"id":68449,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68447\/revisions\/68449"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}